Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with lung cancer. Both conditions share common risk factors, including smoking, hypertension, diabetes, advanced age, and obesity. Lung cancer patients often have preexisting CVD, which worsens their prognosis. The management of these patients requires a comprehensive understanding of the cardiovascular complications of lung cancer treatment. This review discusses the shared risk factors, cardiotoxicities associated with lung cancer therapies, and strategies for the prevention and management of CVD in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Multidisciplinary collaboration among oncologists, cardiologists, primary care physicians, and other providers is essential for optimal care. Common therapies for lung cancer, such as immune checkpoint inhibitors (ICIs), targeted therapies, and chemotherapy, can cause cardiovascular adverse effects, including myocarditis, pericarditis, arrhythmias, heart failure, and hypertension. EGFR inhibitors, BRAF and MEK inhibitors, and ALK inhibitors also have potential cardiotoxic effects. VEGF inhibitors are associated with hypertension and an increased risk of arterial thromboembolic events. Cytotoxic agents like cisplatin and anthracyclines are linked to acute coronary syndrome and cardiotoxicity. Radiotherapy can lead to radiation-induced heart disease, which is influenced by the mean heart dose and other factors. Cardiovascular risk factors in lung cancer patients should be managed proactively, with a focus on controlling hypertension, hyperlipidemia, and diabetes. Patients should be screened for modifiable risk factors, and appropriate interventions should be implemented. For patients receiving ICI therapy, baseline cardiac assessments and regular follow-ups are crucial. Cardiovascular disease screening and surveillance are essential for early detection and management of CVD in lung cancer patients. Guidelines recommend regular monitoring, lifestyle modifications, and pharmacological interventions to minimize cardiovascular complications. A multidisciplinary approach is critical to ensure effective management of CVD in lung cancer patients.Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with lung cancer. Both conditions share common risk factors, including smoking, hypertension, diabetes, advanced age, and obesity. Lung cancer patients often have preexisting CVD, which worsens their prognosis. The management of these patients requires a comprehensive understanding of the cardiovascular complications of lung cancer treatment. This review discusses the shared risk factors, cardiotoxicities associated with lung cancer therapies, and strategies for the prevention and management of CVD in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Multidisciplinary collaboration among oncologists, cardiologists, primary care physicians, and other providers is essential for optimal care. Common therapies for lung cancer, such as immune checkpoint inhibitors (ICIs), targeted therapies, and chemotherapy, can cause cardiovascular adverse effects, including myocarditis, pericarditis, arrhythmias, heart failure, and hypertension. EGFR inhibitors, BRAF and MEK inhibitors, and ALK inhibitors also have potential cardiotoxic effects. VEGF inhibitors are associated with hypertension and an increased risk of arterial thromboembolic events. Cytotoxic agents like cisplatin and anthracyclines are linked to acute coronary syndrome and cardiotoxicity. Radiotherapy can lead to radiation-induced heart disease, which is influenced by the mean heart dose and other factors. Cardiovascular risk factors in lung cancer patients should be managed proactively, with a focus on controlling hypertension, hyperlipidemia, and diabetes. Patients should be screened for modifiable risk factors, and appropriate interventions should be implemented. For patients receiving ICI therapy, baseline cardiac assessments and regular follow-ups are crucial. Cardiovascular disease screening and surveillance are essential for early detection and management of CVD in lung cancer patients. Guidelines recommend regular monitoring, lifestyle modifications, and pharmacological interventions to minimize cardiovascular complications. A multidisciplinary approach is critical to ensure effective management of CVD in lung cancer patients.